Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer Hospital Egypt 57357
• Treatments: Captopril

Criteria

Inclusion Criteria:

• All Acute Myeloid Leukemia and Bone Tumors patients (Osteosarcoma and Ewing's Sarcoma) who didn't receive chemotherapy will be included in the study.

• Written Informed Consent from parents/guardian

Exclusion Criteria:

• Patients who received chemotherapy before starting of the study

• Patients with history of cardiac impairment, (existing or congenital heart disease).

• Patients who show intolerance or contra-indications to ACE-I.

• Patients developing acute (< 2 weeks) cardiotoxicity after the first high-dose chemotherapy (HDC) course.